Background: Second-generation drug eluting stents (DES) may reduce costs and improve clinical outcomes compared to first-generation DES with improved costeffectiveness when compared to bare metal stents (BMS). We aimed to conduct an economic evaluation of a cobalt-chromium everolimus eluting stent (Co-Cr EES) compared with BMS in percutaneous coronary intervention (PCI). Objective: To conduct a cost-effectiveness analysis (CEA) of a cobalt-chromium everolimus eluting stent This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
INTRODUCTION
As the first major drug-device combination product for cardiovascular disease, drug-eluting stents (DES) represented a clinical breakthrough in treatment of patients with coronary artery disease (CAD) [1] . The technology continues to evolve, with the recent development of second-generation DES platforms such as the cobalt chromium (Co-Cr) everolimus-eluting stent (EES). These platforms are comprised of permanent polymer coatings, less toxic antiproliferative drugs (e.g., everolimus or zotarolimus), and thin strut stent designs compared with first-generation DES.
Robust randomized controlled trials (RCTs) and several meta-analyses of RCTs have shown that Co-Cr EES is significantly safer and more effective than bare metal stents (BMS), with lower rates of stent thrombosis (ST), myocardial infarction (MI), and cardiac mortality [2] [3] [4] [5] [6] [7] [8] . A recent patient level meta-analysis of 4,896 patients from five RCTs (including three all comer studies) found that patients receiving Co-Cr EES had significant reductions in cardiac mortality, MI, definite ST, definite or probable ST, and target vessel revascularization (TVR) versus patients receiving BMS [5] . There are also some indications that second-generation DES reduce costs and improve clinical outcomes compared to first-generation DES [9] , with improved cost-effectiveness versus BMS [10] [11] [12] .
The current study leverages the availability of data from the patient level meta-analysis of RCTs to address the cost effectiveness of Co-Cr EES compared to BMS.
METHODS
Type of Analysis and Perspective. The costeffectiveness analysis (CEA) was conducted for a 2-year time horizon from the US Medicare perspective [13] . A 2-year time horizon was selected to align with the patient level meta-analysis [5] and previous costeffectiveness studies of DES compared to BMS [10, [14] [15] [16] [17] . Costs and outcomes at year 2 were discounted at a rate of 3%.
Study Population
The mean age of patients included in the patient level meta-analysis was 67 years and the majority of patients included were male (76%). Type 2 diabetes mellitus was present in approximately 19% of patients. Forty-four percent of all patients received stenting in the setting of primary PCI and more than 87% underwent PCI treatment for an unstable presentation. The methods and results of the meta-analysis have been reported in detail by Valgimigli et al. [5] .
Model Overview
A Markov state transition model was developed in Microsoft Excel 2007 using effectiveness and safety data from the patient level meta-analysis ( Fig. 1) [5] . Patients started the model in the "alive" health state, and during each model cycle of 1 year, could transition to deceased. During each 1-year model cycle, "eventfree" patients could also experience one or more of the following transient events: MI, ST or TVR. Event risks were only available to inform the probability of moving from event-free to a transient event; data was not available to inform movement between the transient events. The data inputs used in the CEA are summarized in Table I .
Transition Probabilities and Event Risks
The risks of mortality, MI, ST, and TVR were informed by the patient level meta-analysis [5] . The authors of the meta-analysis provided the number of patients at risk and the number of events for each treatment group, stratified by year 1 and year 2. The authors also provided cause of mortality (i.e., all-cause or cardiac-related) and type of MI (i.e., TVR-related, any MI).
Resource Use and Unit Costs
The focus of the CEA was costs borne by the US Medicare program, including costs associated with the percutaneous coronary intervention (PCI) procedure (including the stent), TVR, MI, and dual antiplatelet therapy (DAPT). Estimates of resource use and unit costs (2015 US dollars) were obtained from the published literature. Additional technology costs associated with DES versus BMS were included in diagnosisrelated group (DRG) payments.
For patients who experienced TVR, re-intervention could be performed by means of coronary artery bypass graft (CABG) or PCI (with stent or without stent). The proportions of patients receiving CABG (10%) or PCI (90%) were taken from a publication reported by Garg et al. [18] . The breakdown of re-intervention with PCI was assumed to be PCI with DES (56%) and PCI without stent (44%) [18] .
In the patient level meta-analysis, the duration of DAPT (i.e., clopidogrel in addition to aspirin) ranged from 3 months to 24 months for both DES and BMS [5] . The European Society of Cardiology (ESC) guidelines recommend a DAPT duration of at least 1 month for BMS and 6 months for DES [19] . The ACC guidelines recommended a DAPT duration of 1 month for BMS and 12 months for DES [20] . For the base-case analysis, we assumed a DAPT duration of 6 months for BMS and 12 months for DES. Generic pricing of clopidogrel (75 mg) was based on the wholesale acquisition cost (WAC) published in the US Redbook online pricing database [21] . A 20% mark-up was added to the WAC to be more conservative and to arrive at a total monthly acquisition cost of $23.64 that more closely reflected the average wholesale price (AWP) [22] .
An alternative monthly DAPT cost of $91.82 (assuming 50% generic and 50% brand clopidogrel) was evaluated in the sensitivity analyses.
Health Utility
Quality of life impacts were included for CAD, MI, and TVR. A health utility value of 0.85 was applied in the model to patients with CAD and no symptoms [18] . For patients experiencing TVR a health utility decrement of À0.06 was applied for 1 year following the reintervention, irrespective of revascularization with CABG or PCI [18] . For patients experiencing MI, a health utility of 0.75 was applied for 1 year following the MI [18] .
Analysis
The base-case analysis included clinical outcomes from the patient level meta-analysis that were considered to be stent-related: TVR, TVR-related MI, definite ST, and cardiac-related mortality. A secondary analysis was conducted that considered the broader set of clinical outcomes from the meta-analysis: TVR, all MI, definite ST, and all-cause mortality.
One-way sensitivity analyses were conducted in order to test the robustness of the base-case analysis to alternative assumptions and data inputs related to transition probabilities, risks of events, resource use, DAPT therapy costs, and health utility (Table II) [20, [23] [24] [25] . A probabilistic sensitivity analysis (PSA) was conducted to simultaneously quantify the uncertainty in all key model input parameters.
RESULTS

Base-Case Analysis
Results of the base-case analysis (Table III) demonstrated that Co-Cr EES was more efficacious than BMS. Patients who received PCI with Co-Cr EES experienced fewer cardiac-related deaths, TVR-related MIs, ST, and TVRs, 0.015 additional life years, and 0.018 additional QALYs compared with patients who received PCI with BMS. PCI with Co-Cr EES was also associated with cost savings of $236 per patient. The primary drivers of the cost savings were the reduction in TVR and MI rates, which offset the increased costs of the index procedure and DAPT observed with CoCr EES versus BMS.
Results of the secondary analysis (not shown) demonstrated similar results to the base-case analysis. PCI with Co-Cr EES was both more effective (0.009 additional life years and 0.013 additional QALYs per patient) and less costly (-$288 per patient) versus BMS. [23] $160.00 Clopidogrel duration-Co-Cr EES [5] 12 months Clopidogrel duration-BMS [5] 6 months Health Utilities [18] Both 
One-Way Sensitivity Analysis
The base-case results were robust to a number of sensitivity analyses. When inputs were varied by AE20%, results remained cost savings for Co-Cr EES relative to BMS in all cases (not shown). Similarly, when base-case inputs were varied using alternative values taken from published literature [20, [23] [24] [25] , all analyses showed that Co-Cr EES was more effective and less costly versus BMS, with the exception of the cost of clopidogrel, which resulted in a cost of $9,755 per QALY gained (Table IV) . Figure 2 depicts the results of the PSA on the costeffectiveness scatter plot for the base-case analysis (A) and the secondary analysis (B). Each point on each scatterplot represents the incremental QALYs for Co-Cr EES versus BMS (x-axis) and the incremental cost of Co-Cr EES versus BMS (y-axis) for each of the 1,000 model simulations [26, 27] . For the basecase analysis, 88.5% of the model iterations showed Co-Cr EES to be cost savings versus BMS. In 10.6% of the model iterations, Co-Cr EES was more effective and more costly than PCI with BMS. In the remaining model iterations, Co-Cr EES was less effective [28] . Fig. 2 . Results of the probabilistic sensitivity analysis on the cost-effectiveness scatter plot for the base-case analysis (A) and the secondary analysis (B) [28] . QALY 5quality-adjusted life year; USD 5 United States dollars. Fig. 3 . Results of the probabilistic sensitivity analysis using cost-effectiveness acceptability curves for the base-case analysis (A) and the secondary analysis (B) [28] . BMS 5 baremetal stent; Co-Cr EES 5 cobalt chromium everolimus-eluting stent; USD 5 United States dollars.
Probabilistic Sensitivity Analysis
Very similar results were observed for the secondary analysis; Co-Cr EES was cost savings versus BMS in 91.1% of the model iterations and Co-Cr EES was more effective and more costly than BMS in 5.8% of the model iterations. Figure 3 shows the CEACs for both the base-case and secondary analyses. At willingness-to-pay (WTP) thresholds of $50,000 per QALY, the base-case PSA predicted that Co-Cr EES was associated with a 99.5% likelihood of being cost-savings or cost effective. For the secondary analysis, the PSA predicted that Co-Cr EES was associated with a 99.2% likelihood of being cost-savings or cost effective.
DISCUSSION
Statement of Principal Findings
This 2-year CEA found that PCI with Co-Cr EES is more effective and less costly compared with PCI with BMS in contemporary US clinical practice. The basecase analysis found that a patient who received Co-Cr EES experienced an additional 0.018 QALYs and cost savings of $236 compared with a patient who received a BMS. The findings were consistent between the basecase analysis and the secondary analysis that included broader outcomes.
Strengths and Limitations
The evaluation was based on a patient level metaanalysis of RCTs, a research methodology that is widely regarded as the highest level of evidence and has inherent advantages over individual RCTs and aggregate data meta-analyses [29] [30] [31] . Furthermore, the patient population of the RCTs included in the meta-analysis is generally reflective of real-world clinical practice. This analysis was also based on several conservative assumptions, including a short-term time horizon and the assumption that a high proportion of re-interventions employed angioplasty only [32] . Finally, the results of our analyses were robust across a range of sensitivity analyses.
Uncertainty remains regarding the appropriate duration of DAPT for patients receiving Co-Cr EES. A recent meta-analysis of 10 RCTs of DES showed that patients using DAPT for less than 12 months showed lower risk of major bleeding with no significant increase in thrombotic outcomes compared with patients using DAPT for 12 months [33] . A 12-month duration of DAPT for Co-Cr EES was assumed for the basecase analysis, and the results were found to be robust to a wide range of alternative assumptions. However, care should be exercised when generalizing the results of the economic evaluation to environments in which practice patterns, resource utilization, and costs differ from those assumed in this analysis.
Comparison With Other Studies
To our knowledge, this CEA is the first to find that Co-Cr EES is economically dominant versus BMS. Cost savings were driven primarily by significant reductions in MI, ST, and cardiac mortality with Co-Cr EES relative to BMS. Other key drivers of the analysis include the declining price differential between DES and BMS and the availability of generic clopidogrel.
Other recent economic evaluations have reported conflicting results regarding the economic value of DES. In 2010, Remak et al. [11] reported a CEA of patients treated with the Endeavor DES or BMS over 4 years and reported a low cost per QALY of £3,575. Like our analysis, Remak et al. incorporated a reduction in the risk of MI and death for DES, a smaller price difference between DES and BMS ($£500), and relatively low cost of generic clopidogrel ($£35 per month). It is noteworthy that the magnitude of the clinical benefit at 2 years was reported to be lower in the Remak study compared to the current study; however the Remak data extended to 4 years. Schafer et al. [10] reported an economic evaluation of first-generation DES using 3-year, real-world, observational data from the US and reported a high cost per QALY of $87,705 for DES versus BMS. Importantly, Schafer and colleagues did not incorporate a reduction in the risk of MI for DES and assumed a relatively high cost of clopidogrel (i.e., $140 per month). The authors noted that lower generic clopidogrel and DES costs would result in overall cost-savings for DES versus BMS.
In contrast, Barone-Rochette et al. [12] reported that DES was not cost-effective (i.e., at a WTP threshold of e10,000 per revascularization avoided) at a price differential of e1,200 (e2,008), but that it became cost effective at a price differential of e400 (e2,012). No differences in MI, ST, or cardiac mortality were modeled in this analysis. Finally, a 2013 economic evaluation based on Canadian observational data for patients with stable coronary disease also questioned the cost effectiveness of DES and recommended broad use of BMS [24] . However, the observational data were based on patients receiving first-generation stents from 2003 to 2005 and the unit costs of DES vs. BMS (i.e., $2,519 vs. $657, respectively) used in the analysis were also presumably from that timeframe.
Impact on Daily Practice
The findings of this study hold practical importance for payers, policymakers and clinicians evaluating the clinical and economic value of Co-Cr EES and other cardiovascular innovations. As PCI technology and clinical practice rapidly advanced from first-generation DES to Co-Cr EES, it has represented a "moving target" that underscores the importance of updating health technology assessment (HTA) and economic evaluations to reflect changes in economic value over time. In contrast to early analyses involving first-generation DES, our economic analysis based on the highest level of clinical evidence finds that PCI with Co-Cr EES is more effective and less costly than PCI with BMS in contemporary US clinical practice.
CONCLUSIONS
Studies assessing the cost effectiveness of DES versus BMS have reported mixed results due to multiple factors including limitations of first-generation DES. Utilizing the latest data from the US Medicare program and clinical results from a high-quality, patient level meta-analysis of RCTs our study finds that Co-Cr EES is an economically attractive strategy compared with BMS in patients undergoing PCI.
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